Hims & Hers Health
🌱 SurvivorTrust Size
$280M
Peak Price
$55.00
Current Price
$42.00
Return
+320.0%
Peak Market Cap
$12.0B
What Happened
Telehealth and wellness company — THE SPAC success story. Stock went from $10 to $55 with real revenue growth, profitability, and a genuine disruption of healthcare delivery.
Hims & Hers merged with Oaktree Acquisition Corp in January 2021. The company sells telehealth consultations and prescription treatments (hair loss, ED, skincare, mental health) directly to consumers via subscription. Unlike nearly every other SPAC, Hims actually had product-market fit, efficient customer acquisition via social media, and a clear path to profitability. Revenue grew from $272M (2021) to $1.5B+ (2025). The stock hit $55 — making early SPAC investors 5x their money. The rare proof that the SPAC model can work with the right company.
Projections vs. Reality
Projected Revenue
$600M
What they told investors
Actual Revenue
$1.5B
What actually happened
Hype-to-Reality Ratio: 250.0x
Key People
Andrew Dudum
CEO & Founder
Former partner at Atomic VC, built the brand
Howard Marks
SPAC Sponsor (Oaktree)
Legendary value investor, chose wisely
Timeline
2020-09
SPAC merger announced
2021-01
Merger completed
2022-06
Stock dips to $4 (market downturn)
2023-12
GLP-1 weight loss treatments boost stock
2025-01
Stock hits $55, $12B market cap
📄 SEC Filings
View all EDGAR filings for Hims & Hers Health
Risk Scores
Dilution Score
30/100
Insider Profit Index
20/100
Hype-to-Reality Ratio
250.0x
Projected ÷ actual revenue